source
- GSK to start Phase 3 trial of mRNA flu vaccine after strong mid-stage resultsGSK announced it will begin a Phase 3 trial of its mRNA-based influenza vaccine, with enrollment slated to start in September. In a Phase 2 study of 971 adults, the investigational vaccine, which…
- Nine midsize biopharma firms join Trump MFN drug pricing program, covering 89% of branded marketNine midsize biopharma companies have agreed to voluntarily participate in the Trump administration's Most Favored Nation drug pricing program, adding to the 17 large pharmaceutical firms that prev…